Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The mammalian target of rapamycin (mTOR) is a key target in cancer therapy, with rapamycin and its analogs undergoing clinical trials.
• While mTOR inhibition shows promise, particularly in reversing prostate intraepithelial neoplasia, many cancer cells exhibit resistance to these drugs.
• Understanding the mechanisms of rapamycin resistance is crucial for developing more effective cancer treatments.

Purpose of the Study:

• To investigate the molecular mechanisms underlying cancer cell resistance to rapamycin.
• To identify signaling pathways activated by mTOR inhibition that may contribute to drug resistance.
• To explore combination strategies for enhancing the efficacy of mTOR-targeted cancer therapy.

Main Methods:

• Human lung cancer cells were treated with rapamycin to assess its effects on mTOR signaling components (p70S6 kinase, 4E-BP1).
• The phosphorylation levels of Akt and eIF4E were measured following rapamycin treatment.
• The role of phosphatidylinositol-3 kinase (PI3K) in rapamycin-induced signaling was evaluated using the PI3K inhibitor LY294002.
• The impact of combined rapamycin and LY294002 treatment on cancer cell growth and colony formation was assessed.

Main Results:

• Rapamycin treatment suppressed the phosphorylation of p70S6 kinase and 4E-BP1, confirming mTOR pathway inhibition.
• Paradoxically, rapamycin treatment increased the phosphorylation of Akt and eIF4E, indicating activation of survival pathways.
• This rapamycin-induced activation of Akt and eIF4E was dependent on PI3K activity, as shown by LY294002 suppression.
• Combined treatment with rapamycin and LY294002 demonstrated enhanced inhibition of cancer cell growth and colony formation.

Conclusions:

• mTOR inhibition by rapamycin triggers compensatory activation of PI3K/Akt and eIF4E survival pathways, contributing to drug resistance.
• These activated pathways act as a negative feedback mechanism, attenuating the anti-cancer effects of rapamycin.
• Combining mTOR inhibitors with PI3K or Akt inhibitors offers a promising strategy to overcome rapamycin resistance and enhance cancer therapy efficacy.